Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Novo Nordisk's eternal rival, Eli Lilly, recently decreased its full-year 2024 guidance again for this reason. According to Eli Lilly's management, this market grew by 45% in the fourth quarter ...